News

Patients With GI Intolerance Prefer Injectable Ibandronate


 

TORONTO — Women with postmenopausal osteoporosis who had previously discontinued oral bisphosphonate therapy because of gastrointestinal intolerance preferred an intravenous, every-3-month regimen of ibandronate over a monthly oral regimen, Dr. E. Michael Lewiecki reported at a world congress on osteoporosis.

Adherence was addressed in a 12-month, open-label multicenter study that included 542 patients with osteoporosis or osteopenia who had stopped daily or weekly treatment with oral alendronate or risedronate because of perceived or actual symptoms such as heartburn and acid reflux. All received supplemental vitamin D (400 IU/day) and elemental calcium (1,000 mg/day).

Patients were given the choice of oral ibandronate, 150 mg once monthly, or 3 mg intravenously every 3 months. The intravenous injection takes 15-30 seconds to complete. A total of 396 (73%) of patients chose the intravenous regimen, while 146 (27%) chose the oral route.

They were permitted to switch treatment groups once during the study if they experienced adverse effects, he noted.

Severity and frequency of gastrointestinal symptoms and other side effects were evaluated with surveys administered at baseline and at months 1, 4, 7, and 10.

Available data indicate that adherence to both regimens at 6 months was high, at 94.5%. Actual duration of study medication intake divided by maximum duration of intake and a threshold of 75% or more was used to define adherence, according to Dr. Lewiecki of New Mexico Clinical Research and Osteoporosis Center, Albuquerque.

Among patients receiving the oral drug, adherence was 87.7%, while adherence was 94.9% among those receiving the intravenous formulation, Dr. Lewiecki wrote in a poster session; the meeting was sponsored by the International Osteoporosis Foundation.

Among patients who chose the intravenous route of administration, 147 (37.1%) had a history of fracture as an adult, compared with 36 (24.7%) of those who chose the oral drug.

Thus far, 26 patients have switched their route of administration. Eleven switched from oral to intravenous ibandronate because of gastrointestinal intolerance, while 15 switched from intravenous to oral for reasons including influenzalike symptoms and injection-site reactions.

By month 4, 28.1% and 36.6% of patients on the oral and intravenous drugs, respectively, reported improvements in gastrointestinal tolerance compared with baseline.

“Based on these findings, it appears that patients who had previously discontinued weekly or daily oral bisphosphonates because of gastrointestinal intolerance prefer intravenous dosing, and that patients with a previous fracture are even more likely to do so than patients without a previous fracture,” Dr. Lewiecki concluded.

Recommended Reading

Absorption Similar for Nasal, Injected Teriparatide
MDedge Rheumatology
Island Study to Research Genes, Osteoporosis Link
MDedge Rheumatology
Jaw Osteonecrosis Occurred in 1% of Cancer Patients on IV Bisphosphonate
MDedge Rheumatology
Osteoporosis Treatment Guidance Changing
MDedge Rheumatology
Look Past First Cause of Secondary Osteoporosis
MDedge Rheumatology
Denosumab at Least as Effective as Alendronate
MDedge Rheumatology
IV Ibandronate Found to Boost Bone Density as Well as Daily Oral Dosing
MDedge Rheumatology
Weight, Sport Predict Varsity Women's BMD
MDedge Rheumatology
Continue Osteoporosis Therapy Even in Nonresponders
MDedge Rheumatology
WHO Osteoporosis Guidelines Tailor Treatment to Resources
MDedge Rheumatology